Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Clinical Trial of Temozolomide Plus Apatinib in Newly Diagnosed High-grade Glioma

Next Previous
Trial Profile

A Randomized Controlled Clinical Trial of Temozolomide Plus Apatinib in Newly Diagnosed High-grade Glioma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Rivoceranib (Primary) ; Temozolomide
  • Indications Glioma
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Jan 2019 Planned End Date changed from 1 Nov 2020 to 1 Jul 2022.
    • 06 Jan 2019 Planned primary completion date changed from 1 May 2020 to 1 Feb 2022.
    • 06 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top